You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
Brief News on Innovation
Company News Brief News on Innovation
TaurusTrio AR TAVR SYSTEM COMPLETED ALL PATIENT ENROLLMENT OF ITS MULTI-CENTER PIVOTAL CLINICAL TRIAL
2024-01-29 09:35:55

In January 2024, TaurusTrio AR TAVR System  successfully completed patient enrollment in its multicenter pivotal clinical trial. Since July 2023, the study has exceeded expectations by enrolling 116 patients with aortic regurgitation in 6 months, leading the industry in development progress. TaurusTrio is a transfemoral aortic regurgitation indicated TAVR product exclusively licensed-in by Peijia Medical from JenaValve Technology, Inc. and is now commercially available in Hong Kong, China.


Top